Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2011

View Archived Issues

Genus Oncology's GO-203-2c enters phase I trial in solid tumors

Mutant EPO lacking erythropoietic activity protects against ischemic brain injury

Modified mRNA molecules could be alternatives to DNA-based therapies

Regulating adenosine signaling improves symptoms of sickle cell disease

Programmable bio-nano-chips offer rapid and low-cost biomarker analysis

Creatine kinase levels predict hemorrhagic transformation in patients receiving alteplase for stroke

BPX-101 shows promise in phase I/II trial in metastatic prostate cancer

Tibotec begins recruitment in phase III trials of HCV protease inhibitor TMC-435

Novel renin inhibitors discovered at sanofi-aventis

Roche patents new activators of glucokinase

New inhibitors claimed of cGMP-dependent 3',5'-cyclic phosphodiesterase

Amgen reviews highlights of fourth quarter 2010

Vitae Pharmaceuticals claims new 11-beta-HSD1 inhibitors

UCSD clears Stemedica's phase I/II trial of allogeneic stem cells for stroke

Eisai divulges novel beta-secretase 1 inhibitors

Micell Technologies enrolls first patient in DESSOLVE-II trial of MiStent DES

Spanish scientists identify novel phenalenones with cytotoxic effects

Merck Serono Europe withdraws MAA for Movectro

EMA's CHMP recommends approval of Hizentra

Conatus Pharma begins phase II trial of CTS-1027 in hepatitis C

BioDelivery Sciences on track with phase III trial of BEMA Buprenorphine in chronic pain

Apricus Bio and FDA discuss SPA for phase III PrevOnco trial

Cytos obtains E.U. funding to help develop vaccines against emerging viral diseases

Antisense Therapeutics begins final preparations for first clinical trial of ATL-1103

FDA approves Corifact for prophylactic treatment of congenital coagulation factor XIII deficiency

CHMP issues positive opinion on Novartis' Rasilamlo for high blood pressure

Intercell's JE vaccine enters pivotal phase II/III pediatric trial in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....